The drug in question – codenamed GS-1811 (formerly JTX-1811) – is an antibody drug designed to selectively deplete T regulatory cells in the tumour microenvironment that has been taken into phase 1 clinical testing as a monotherapy and in combination with PD-1 inhibitor zimberelimab for solid tumours.
Gilead licensed GS-1811 in 2020 in a deal valued at around $800 million, including $85 million upfront and a $35 million equity investment – after Bristol-Myers Squibb returned rights to GS-1811 – but it now wants full control and rights to the drug.
